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Several features of the model will undoubtedly stimulate more questions than they answer. To crystallize unglycosylated mouse P-gp purified from the yeast Pichia pastoris-an accomplishment that had eluded all others in the field-Aller et al. 2 had to eliminate ATP, ATP analogs and magnesium from the crystallization medium. The structure (Fig. 1a) shows the two halves of the potential ATP-binding sites 30 Å apart-a considerable distance given that these regions must interact to bind ATP during the catalytic cycle.
The authors speculate that the structure in Figure 1a represents mouse P-gp in a "pretransport state" and that binding of ATP during the catalytic cycle probably results in dimerization of the ATP sites. However, because ATP concentrations in the cell (3-5 mM) always far exceed the affinity of the transporter for ATP (K mATP 0.3-1 mM), it seems unlikely that P-gp P-gp can remove hydrophobic drugs directly from the membrane 6 . The drug-binding cavity is composed of parts of the transmembrane segments from both halves of P-gp, especially transmembrane helices 4, 5 and 6 and 10, 11 and 12, as predicted from previous photoaffinity labeling studies 7, 8 and cross-linking analyses 9 . Although not of sufficiently high resolution to discern individual side chains, the structures make many clear predictions about residues likely to be involved in drug binding that can and will be tested by mutational analysis. Interestingly, P-gp crystallizes into identical crystal forms in the absence of any inhibitor (PDB:3G5U) and in the presence of one (PDB:3G60) or two inhibitors (PDB:3G61) in the central cavity. The three structures display few changes in crystal cell parameters, the overall conformation of the protein (0.6 Å root-mean-square deviations for all Cα atoms) and the local environment of the binding sites, except for a few changes Multidrug transporters are the bane of pharmacologists as they diminish the efficacy of many drugs by pumping them out of bacteria and mammalian cells 1 . The multidrug efflux pump P-glycoprotein (P-gp), for example, contributes to multidrug resistance in about half of human cancers. In a recent paper in Science, Aller et al. 2 reported X-ray crystal structures of mouse P-gp to 3.8 Å resolution-the highestresolution structures of a mammalian multidrug transporter to date. The three structures show P-gp alone and P-gp bound to two stereoisomers of a novel cyclic hexapeptide inhibitor, all in the absence of ATP. These results reinforce many of the conclusions derived previously from detailed biochemical studies and illustrate the pitfalls of using static structures to understand conformationally dynamic molecules such as ATP-binding cassette (ABC) transporters.
The mammalian P-gp transporters (encoded by the MDR1 (ABCB1) gene in the human and the mdr1a (abcb1a) and mdr1b (abcb1b) genes in the mouse) were first cloned in 1986 (refs. 3,4), and their essential physiological, biochemical and pharmacologic features have been well described 5 . However, controversy remains over how P-gp recognizes hundreds of different hydrophobic drugs and pumps them out of the cell and how similar it is to the 47 other known members of the human ABC transporter family. High-resolution crystal structures of P-gp would be invaluable for investigating these questions and for designing therapeutic P-gp antagonists.
Although the structures solved by Aller et al. 2 lack the high resolution needed to settle most of the remaining controversies, they do provide useful new information. The essential features are a large, 6,000 Å 3 internal cavity to which hydrophobic drugs can bind in various orientations and at different locations, as well as two portals in the inner leaflet part of the protein that allow entry of hydrophobic drugs from the lipid bilayer. The structures support the "hydrophobic vacuum cleaner" model first proposed to explain the observation that ferences among the transporters. Nevertheless, this study gives hope that persistence will be rewarded and encourages the field to continue to seek crystals of other mammalian P-gps that diffract X-rays to higher resolution and that represent more physiologically relevant conformations.
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